Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 18/20 | 0.47 |
| ▸ | HTR7 | P34969 | 18/20 | 0.47 |
| ▸ | DRD2 | P14416 | 6/20 | 0.47 |
| ▸ | HTR6 | P50406 | 4/20 | 0.47 |
| ▸ | HTR2A | P28223 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24309839 | 1.00 | HTR1A (0.47) | HTR1AHTR7DRD2HTR6HTR2A | |
| SCHEMBL26807601 | 0.87 | HTR1A (0.40) | HTR1AHTR7DRD2HTR6NLRP3 | |
| SCHEMBL24309844 | 0.83 | HTR1A (0.32) | HTR1AHTR7DRD2HTR6HTR2A | |
| SCHEMBL26810547 | 0.79 | HTR1A (0.48) | HTR1AHTR7DRD2HTR6HTR2A | |
| SCHEMBL29566524 | 0.79 | NLRP3 (0.35) | HTR1AHTR7DRD2HTR6NLRP3 | |
| SCHEMBL24309657 | 0.79 | NLRP3 (0.35) | HTR1AHTR7DRD2HTR6NLRP3 | |
| SCHEMBL26807593 | 0.79 | HRH3 (0.37) | — | |
| SCHEMBL26807590 | 0.78 | HRH3 (0.42) | HTR1AHTR7 | |
| SCHEMBL26807599 | 0.78 | FLT3 (0.34) | HTR6 | |
| SCHEMBL24309636 | 0.77 | NLRP3 (0.34) | HTR1AHTR7NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| EP-4225748-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | HTR1A 4018/4885HTR7 3833/4885DRD2 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.